Dr. Sophie Claudel, currently a nephrology fellow at Boston Medical Center and a clinical instructor at Boston University Chobanian & Avedisian School of Medicine, has been awarded the Akebia CSN Fellowship. Her research centers on elucidating the complex relationship between chronic kidney disease and cardiovascular disease, a co-morbidity that remains one of the leading causes of mortality in CKD patients. Through detailed molecular and proteomic analyses, Dr. Claudel aims to uncover the pathways that contribute to vascular injury triggered by early kidney damage, with the ultimate objective of identifying novel therapeutic targets that could arrest or reverse disease progression.

Concurrently, Dr. Liz Kiernan, a clinical research fellow at the University of Washington School of Medicine, focuses her expertise on endothelial cell function in the context of kidney diseases. Using state-of-the-art single-cell sequencing technologies, Dr. Kiernan endeavors to map specific molecular markers indicative of endothelial injury. The significance of her work lies in its potential to revolutionize diagnostics by enabling non-invasive methods to detect kidney pathology much earlier. Furthermore, it supports the development of precise, personalized treatment strategies to mitigate damage associated with diabetic nephropathy and acute kidney injury.

Since its launch in 1989, the CSN Program has been pivotal in advancing nephrology research by providing critical funding to young investigators who later emerge as leaders and mentors within the kidney health community. The success stories stemming from this program underscore its importance in nurturing scientific talent dedicated to unraveling the complexities of kidney disease pathways and treatment modalities. The 2026 fellowships awarded to Dr. Claudel and Dr. Kiernan are generously financed through partnerships with Akebia Therapeutics and the HFO Foundation, whose contributions enable sustained investment in transformative kidney research.

Dr. Claudel’s investigative work carefully dissects the molecular interplay responsible for albuminuria—a hallmark of early kidney injury—and its systemic effects on blood vessels. This intersection between renal and cardiovascular health remains an underexplored frontier, particularly during the asymptomatic phase where intervention would yield maximum benefit. By focusing on proteins and signaling cascades implicated in this process, her research not only promises new avenues for early detection but also the design of innovative therapies that target kidney-vascular crosstalk before irreversible pathological damage ensues.

Similarly, Dr. Kiernan’s approach harnesses the granularity offered by advanced single-cell RNA sequencing to delineate endothelial cell heterogeneity in kidney biopsies obtained from patients suffering from diabetic kidney disease and acute kidney injury. Her aim is to identify and characterize specific transcriptomic signatures linked to endothelial dysfunction. Understanding these molecular footprints holds enormous promise in refining prognostication models and in tailoring interventions that could effectively halt or even reverse endothelial damage, thereby preserving kidney function and improving patient outcomes.

Both researchers emphasize the critical importance of early detection and intervention in kidney disease. Dr. Claudel highlights how kidney and heart diseases are interconnected through poorly understood molecular pathways that are particularly elusive during initial silent injury phases. Her research targets these early molecular events to develop interventions that could halt disease progression at a stage when treatment efficacy is highest. Dr. Kiernan, on the other hand, is driven by the potential of modern scientific tools to identify early disease markers, which she believes will usher in a new era of personalized nephrology where treatment is specifically tailored to molecular profiles.

Their complementary research strategies represent a holistic assault on the multifactorial nature of CKD and its cardiovascular complications. Dr. Claudel’s proteomic and genomic focus on systemic vascular injury dovetails with Dr. Kiernan’s molecular dissection of localized endothelial dysfunction, together forming a broader understanding of the pathophysiological networks at play. This synergy holds promise not just for academic insights but also for clinical applications that will significantly improve early diagnosis, disease monitoring, and targeted treatment options for millions globally.

Underpinning their research is a firm commitment to the mission of the American Kidney Fund, which seeks not only to alleviate the burden of kidney disease but also to cultivate scientific innovation capable of driving foundational change in patient care. The AKF’s investment in these early-career investigators reaffirms the fund’s strategic focus on research that addresses the unmet medical needs of vulnerable patient populations suffering from chronic kidney disease and its devastating sequelae.

Dr. Claudel brings to her fellowship a robust background combining clinical training with research experience at the National Institutes of Health, complemented by her work at Boston Medical Center. Her multidisciplinary expertise equips her to bridge clinical nephrology with molecular science, a critical skill set to translate laboratory findings into therapeutic advancements that can be rapidly implemented in patient care.

Likewise, Dr. Kiernan’s clinical research fellowship at the University of Washington is supported by a comprehensive academic journey beginning with a Bachelor of Science in biochemistry, followed by medical training and rigorous internal medicine residency and leadership roles. This diverse academic foundation and clinical experience empower her to integrate cutting-edge molecular techniques into research that holds direct translational potential for improved clinical diagnostics and therapeutics in kidney disease.

The AKF’s CSN Program not only fosters scientific excellence but also facilitates important collaborations and mentorship that are vital for sustaining innovation within nephrology. By supporting researchers like Dr. Claudel and Dr. Kiernan, who combine cutting-edge scientific methodology with a strong patient-centered ethos, the program continues its legacy of nurturing the leaders who will define the future of kidney care.

The endorsement of this program by prominent stakeholders such as Akebia Therapeutics and the HFO Foundation further accentuates the importance of public-private partnerships in advancing nephrology research. These collaborations enable substantial resource allocation towards projects that have the highest potential for clinical impact, ultimately benefiting patients at every stage of kidney disease progression.

In summary, the award of the 2026 Clinical Scientist in Nephrology Program fellowships to Dr. Claudel and Dr. Kiernan heralds a new chapter in kidney disease research, marked by a sophisticated understanding of molecular pathophysiology and a commitment to precision medicine. Their groundbreaking work promises to bridge crucial knowledge gaps in the nexus of kidney and cardiovascular diseases and to catalyze the development of personalized diagnostic tools and therapeutic interventions. This innovative research trajectory is poised to significantly enhance quality of life and survival for those affected by chronic kidney disease.

Subject of Research: Molecular and cellular mechanisms linking chronic kidney disease to cardiovascular complications, focusing on early kidney damage and endothelial injury using proteomic analyses and single-cell sequencing.

Article Title: American Kidney Fund Awards 2026 Clinical Scientist in Nephrology Fellowships to Dr. Sophie Claudel and Dr. Liz Kiernan

News Publication Date: April 21, 2026

Web References:
https://www.kidneyfund.org/professionals-and-research/clinical-scientist-nephrology-program
https://www.kidneyfund.org/

Keywords: Chronic kidney disease, cardiovascular disease, nephrology research, endothelial injury, albuminuria, single-cell sequencing, molecular diagnostics, personalized medicine, kidney and heart disease connection, early detection, targeted therapies, kidney biopsy

Nephrotic syndrome is characterized by the kidney’s inability to adequately filter proteins, leading to significant proteinuria, hypoalbuminemia, edema, and increased susceptibility to infections. The burden of disease is amplified in adult patients who experience frequent relapses or dependence on corticosteroids, often resulting in chronic complications and diminished quality of life. The challenge lies in balancing effective disease control while minimizing exposure to glucocorticoids, which are well known for their myriad side effects including metabolic disturbances, osteoporosis, and increased cardiovascular risk.

The double-blind randomized controlled trial conducted at The University of Osaka enrolled 66 adult participants diagnosed with FRNS or SDNS. Participants were randomly assigned to receive either rituximab or a placebo, with the primary endpoint being relapse-free survival at 49 weeks. Rituximab exerts its immunomodulatory effect by specifically depleting circulating B lymphocytes, which are believed to drive the pathogenic autoimmune processes underlying nephrotic syndrome flares. The hypothesis rested on whether the B cell depletion strategy effective in children also translates to sustained remission in adults.

At the culmination of the 49-week follow-up period, the study revealed that 87.4% of patients treated with rituximab maintained remission without relapse, in stark contrast to the 38.0% remission rate in the placebo group. This striking disparity underscores rituximab’s potent preventative capability against disease exacerbation in adult patients, bolstering the understanding of immunopathological mechanisms shared between pediatric and adult nephrotic syndrome. It further opens the door to redefining standard care protocols for adult sufferers.

Beyond the initial treatment phase, the trial demonstrated that patients who relapsed on placebo and subsequently received rituximab experienced extended relapse-free intervals, with a mean duration of 49.0 weeks compared to 30.8 weeks on placebo. This durability of response emphasizes rituximab’s potential to induce sustained immunological remission, thus lessening the frequency of relapses and the associated clinical toll. The findings advocate for the early introduction of rituximab in appropriate adult patients rather than its relegation to salvage therapy.

Crucially, the study addressed safety concerns that often deter clinicians when considering immunosuppressive agents in adults. Rituximab was remarkably well tolerated, with no severe drug-related adverse effects reported throughout the study period. Serious adverse events occurred at nearly equivalent rates in both rituximab and placebo groups (3.1% vs 2.9%, respectively). These safety findings reinforce rituximab’s favorable risk-benefit profile and support its broader utilization in refractory nephrotic syndrome cases.

An additional therapeutic advantage observed was a reduction in corticosteroid dependency. Given that long-term corticosteroid use can precipitate serious side effects such as Cushing syndrome, diabetes, and increased infection risk, minimizing steroid exposure is a paramount goal for nephrologists. Rituximab’s ability to maintain remission without ongoing high-dose steroid therapy represents a critical stride towards safer, sustainable disease management and improved patient quality of life.

Immunologically, the pathogenesis of nephrotic syndrome involves aberrant activation of B cells and subsequent dysregulation of T cell responses and podocyte injury. Rituximab’s selective targeting of CD20 eliminates these dysfunctional B cells, thereby dampening the autoimmune cascade thought to precipitate proteinuria and glomerular damage. This mechanistic insight aligns with the observed clinical efficacy and positions rituximab as an immunologically rational therapy that transcends symptomatic control.

The groundbreaking nature of this trial, published in JAMA, will likely catalyze a paradigm shift in nephrology, where targeted biologic therapies complement or supersede traditional immunosuppressants in adult nephrotic syndrome. The results resonate with the broader trend towards precision medicine, employing molecular understanding to tailor interventions and optimize outcomes for complex chronic diseases.

Professor Yoshitaka Isaka, lead author of the study, emphasizes, “Our findings mark a pivotal moment. Having a therapeutic agent that not only effectively prevents relapse but is also well tolerated provides adult patients a new beacon of hope.” Additionally, co-author Assistant Professor Yusuke Sakaguchi highlights the improved quality of life prospects as patients potentially reduce their reliance on steroids and endure fewer disease flares, mitigating healthcare costs and personal morbidity.

With the trial data now publicly accessible, nephrologists worldwide can anticipate integrating rituximab into their armamentarium for adult FRNS and SDNS, pending regulatory approvals. Meanwhile, ongoing research is poised to investigate optimal dosing regimens, long-term outcomes, and combinatory strategies that synergize rituximab with other emerging immunotherapeutics, further refining patient-centered care.

This landmark clinical trial from The University of Osaka not only validates rituximab’s translatable efficacy into adult populations but also embodies a broader scientific endeavor to harness cutting-edge biologics in tackling autoimmune kidney diseases. As adults with nephrotic syndrome frequently face relentless relapses and steroid toxicity, rituximab’s arrival heralds a new era of hope, clinical innovation, and transformative patient care.

Subject of Research: People

Article Title: Rituximab for relapsing nephrotic syndrome in adults; A Randomized Clinical Trial

News Publication Date: 5-Nov-2025

Web References: https://doi.org/10.1001/jama.2025.19316

Image Credits: Yoshitaka Isaka

Keywords: Health and medicine, Antibodies, Clinical studies, Controlled trials, Drug research, Immunology, Medical treatments, Nephropathies, Urology